National Institute of Allergy & Infectious Diseases: Peer-Reviewed Data Shows Remdesivir for COVID-19 Improves Time to Recovery
May 23, 2020
May 23, 2020
WASHINGTON, May 23 -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release on May 22:
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published in The New England Journal of Medicine. The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of . . .
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published in The New England Journal of Medicine. The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of . . .